High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
19 avr. 2017 15h26 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Jennifer Jaff Center Merges with Patient Advocate Foundation
02 mai 2016 09h14 HE
|
Patient Advocate Foundation
HAMPTON, Va., May 2, 2016 (GLOBE NEWSWIRE) -- The Jennifer Jaff Center, a respected national nonprofit for those suffering from chronic illness, has partnered with Patient Advocate Foundation to...
GENETHERA, INC. ISSUES COMMENTS ON THE FIRST INTERNATIONAL RESEARCH SYMPOSIUM ON MAP AND CROHN'S DISEASE.
29 sept. 2015 09h43 HE
|
GeneThera
WESTMINSTER, Colo., Sept. 29, 2015 (GLOBE NEWSWIRE) -- GeneThera, Inc. (OTC: GTHR) as a service to its shareholders and the general public is pleased to release comments on the first Symposium on...
RedHill Biopharma to Host First Quarter 2015 Financial Results Conference Call on April 30, 2015
21 avr. 2015 07h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
13 févr. 2015 10h18 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Reports Results for the First Quarter of 2014
30 avr. 2014 11h00 HE
|
RedHill Biopharma Ltd.
Key financial highlights include:
A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...
Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
28 avr. 2014 21h51 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...
Mesoblast Reports Strong Half-Year Financial Results
25 févr. 2014 17h00 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
25 févr. 2014 08h00 HE
|
RedHill Biopharma Ltd.
2013 Key Highlights Include:
Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...
Boardroom Radio Interview with Mesoblast Chief Executive
02 févr. 2014 20h06 HE
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...